The role of mitomycin in treating lung cancer
Author Information
Author(s): Sculier J P, Ghisdal L, Berghmans T, Branle F, Lafitte J J, Vallot F, Meert A P, Lemaitre F, Steels E, Burniat A, Mascaux C, Paesmans M
Primary Institution: European Lung Cancer Working Party (ELCWP)
Hypothesis
What is the role of mitomycin in the treatment of non-small cell lung cancer?
Conclusion
Mitomycin is effective for non-small cell lung cancer but does not improve survival when used with other drugs.
Supporting Evidence
- 5 trials with 202 patients showed a 25% overall response rate for mitomycin as single-agent chemotherapy.
- 10 randomized phase III trials with 1769 patients showed no survival advantage for mitomycin in combination therapy.
- 4 trials with 139 patients assessed mitomycin as salvage therapy, showing marginal activity.
Takeaway
Mitomycin can help treat lung cancer, but it doesn't make patients live longer when used with other medicines.
Methodology
A systematic review and meta-analysis of trials assessing mitomycin's effectiveness in non-small cell lung cancer.
Limitations
The meta-analysis did not show a survival advantage for mitomycin-containing regimens.
Participant Demographics
Patients with non-small cell lung cancer across multiple trials.
Statistical Information
Confidence Interval
95% CI 19–31 for response rate; 95% CI 0.83–1.10 for hazard ratio.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website